ClinicalTrials.gg
Not yet recruitingNCT07876596Updated Oct 15, 2026

A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080

A Phase 1 interventional study of HRS-8080 and Rifampicin in Breast Cancer, sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing HRS-8080 in Breast Neoplasms — 8 open to participants now, 8 under way, 3 of them phase 3. HRS-8080 · Breast Neoplasms.

Planned enrollment
9th of 11
18 · median 180
Started
2026
with 4 others
Phase 1
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
11 of 11
Shandong Suncadia Medicine Co., Ltd.

Among the 11 studies testing HRS-8080 in Breast Neoplasms, this one is the 9th largest by planned enrollment, is one of 5 that started in 2026, is one of 4 in phase 1, and was the 11th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

8 of the 11 studies testing HRS-8080 in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About HRS-8080

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing HRS-8080 in Breast Neoplasms, or all of them as a file.
02

Study summary

A single-center, single-arm, open-label, fixed-sequence study is planned to enroll 18 healthy participants (6-9 females). The study consists of a screening period, an observation period, and a safety follow-up period.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed before the trial; fully understood the trial content, procedures, and possible adverse reactions; able to complete the study per protocol.
  2. Healthy participants aged 18-55 years (inclusive) at the time of signing informed consent.
  3. At screening, male body weight ≥ 50.0 kg, female body weight ≥ 45.0 kg, and 19.0-28.0 kg/m² (inclusive).
  4. Healthy participants confirmed by the investigator at screening and baseline to have no abnormalities, including medical history, general physical examination, vital signs, laboratory tests (blood routine, urinalysis, blood biochemistry, and coagulation function), and .
  5. Participants of (including partners) agreed to have no plans for pregnancy or sperm/egg donation from informed consent until 3 months after the last dose, and voluntarily used highly effective (including partners); female participants of childbearing potential must have a negative serum HCG test within 7 days before enrollment and must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  1. Any or interfering disease involving the cardiovascular, endocrine, nervous, digestive, respiratory, urogenital, hematologic, immunologic, psychiatric, or metabolic systems.
  2. Surgery within 6 months before screening, planned surgery during the study, or prior surgery affecting gastrointestinal absorption (e.g., gastrectomy, enterectomy, bariatric surgery).
  3. Blood donation or major blood loss (≥ 400 mL), transfusion, or use of blood products within 3 months before screening.
  4. Allergic constitution, including severe drug allergy or drug ; history of allergy to HRS-8080, rifampicin, rifamycin, or their .
  5. Frequent use of sedatives, hypnotics, or other addictive drugs; history of drug abuse within 1 year before screening; positive urine drug abuse screen.
  6. Use of hepatotoxic drugs (e.g., isoniazid, pyrazinamide, methotrexate, leflunomide, valproate, amiodarone, acetaminophen, dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for > 7 consecutive days within 2 months before screening.
  7. Participation in any clinical trial with an drug within 3 months before first dosing.
  8. Use of any drug altering hepatic enzyme activity within 28 days before dosing.
  9. Use of any prescription drug or herbal medicine within 1 month, or any OTC drug or food supplement (including vitamins, calcium tablets) within 2 weeks before first dosing.
  10. Smoking > 5 cigarettes/day within 3 months before screening and unable to stop tobacco use during the study.
  11. Frequent alcohol use within 6 months before screening (> 14 units/week; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine) and unable to stop alcohol during the study; positive alcohol breath test.
  12. Clinically significant abnormalities in vital signs, physical examination, 12-lead , abdominal ultrasound, chest X-ray, blood routine, blood biochemistry, urinalysis, or coagulation at screening.
  13. Any positive result for , anti-, anti-TP, or anti-.
  14. Intake of > 8 servings (1 serving = 250 mL) of caffeine-containing beverages or equivalent within 48h before first dosing and unable to abstain during the study.
  15. Intake of methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) within 48h before first dosing until study withdrawal and unwilling to stop.
  16. Intake of grapefruit-containing beverages or foods within 7 days before first dosing until study withdrawal and unwilling to stop.
  17. Special dietary requirements or inability to comply with a standardized diet.
  18. Live/attenuated vaccine within 3 months before first dosing, or planned live/attenuated/inactivated vaccine during the study (until last follow-up).
  19. Dysphagia.
  20. History of needle or blood phobia, poor venous access, difficult blood collection, or intolerance to venipuncture.
  21. Female participants who are pregnant or lactating.
  22. Any other condition deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    HRS-8080 and Rifampicin group

    HRS-8080, oral; Rifampicin, oral.

    Drug: HRS-8080 · Drug: Rifampicin

Interventions

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Primary PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  2. Area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-t)

    Primary PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  3. Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-∞)

    Primary PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

Secondary outcomes

  1. Time to Maximum Concentration (Tmax)

    Other PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  2. Elimination Half-Life (t1/2)

    Other PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  3. Apparent Oral Clearance (CL/F)

    Other PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  4. Apparent Volume of Distribution (Vz/F)

    Other PK parameters of HRS-8080.

    Time frame: Day 1 to Day 15.

  5. The incidence and severity of adverse events (AEs)

    Safety and tolerability as assessed by the incidence and severity of AEs.

    Time frame: Day 1 to Day 22.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 3 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2026
First posted
Oct 15, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07876596
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Hongxiu Wang
Contact
hongxiu.wang.hw391@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-8080

Start the discussion